BREAST

SOFT(IBCSG24-02/BIG 2-02)

Suppression of Ovarian Function Trial.  A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer Tamoxifen versus Ovarian Function Suppression + Tamoxifen versus Ovarian Function Suppression + Exemestane

NSABP

A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil (5-FU), Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients with Node-Negative Breast Cancer

B-36

B-38

A Phase III adjuvant trial comparing three chemotherapy regimens in women with node-positive breast cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); dose-dense (DD) Doxorubicin/Cyclophosphamide followed by DD Paclitaxel (DD AC→P); DD AC followed by DD Paclitaxel plus Gemcitabine (DD AC→PG)

B-39

A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer

SWOG S0307

Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

BRE 63

A Phase II Trial of Combination Gemcitabine Carboplatin with or without Trastuzumab in Patients with Metastatic Breast Cancer

NCIC CTG

A Randomized Phase III Trial of Exemestane versus Anastrozole in Postmenopausal Women with Receptor-Positive Primary Breast Cancer

MA 27

Perifosine 208

A Phase II Trial of Two Schedules of Perifosine in Combination with Endocrine Therapy for Patients with Estrogen Receptor or Progesterone Receptor Positive Metastatic Breast Cancer

BRE 73

Phase II Trial of Dose Dense Neoadjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced and/or Inflammatory Breast Cancer

BRE 89

Phase II Trial of Vinflunine with or without Trastuzumab in Patients with Metastatic Breast Cancer

GE JUNCTION AND STOMACH

GIST

Gastrointestinal Stromal Tumors (GIST) Registry Protocol

SWOG S0414

Cetuximab Plus Cisplatin, Irinotecan and Thoracic Radiotherapy (TRT) for Locally Advanced (Non-Metastatic), Clinically Unresectable Esophageal Cancer: A Phase II Trial with Molecular Correlates

SWOG S0356

Oxaliplatin plus Protracted Infusion 5-Fluorouracil and Radiation for Potentially Curable Esophageal Cancer: A Phase II Trial with Molecular Correlates

CALGB

A Phase III Trial of Adjuvant Chemoradiation after Resection of Gastric and Gastroesophageal Adenocarcinoma

80101

COLORECTAL

NSABP R-04

A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum

MACCO-A
(MCC 13449)

Microarray analysis of colon cancer outcome-A

C-08

GI 65

Phase II Study of 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in the Adjuvant Treatment of Patients with Stage II/III Rectal Cancer

XELOX Colorectal

“XELOX – A-DVS” (Dense vs. Standard): A Randomized Study of Intermittent Capecitabine in Combination with Oxaliplatin (XELOX Q3W) and Bevacizumab versus Intermittent Capecitabine in Combination with Oxaliplatin (XELOX Q2W) and Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer

GENITOURINARY

CALGB

A Randomized, double-blind, placebo-controlled phase III study of early versus standard Zoledronic acid to prevent skeletal related events in men with prostate cancer metastatic to bone

90202

Perifosine 215

A Placebo-Controlled, Double-Blind Trial of Perifosine in Combination with Docetaxel and Prednisone for Patients with Metastatic Androgen Independent Prostate Cancer

HEMATOLOGICAL

ECO-1

A Phase II study using Alemtuzumab combined with Fludarabine for the treatment of B-cell chronic lymphocytic leukemia (B-CLL)

LymphoCare

An Observational Study of Treatment, Outcomes and Prognosis in Patients with Follicular Non-Hodgkin’s Lymphoma

LYM 28

Phase II Trial of Brief Duration Combination Chemotherapy (CNOP or CVP) and Rituximab with Prophylactic Pegfilgrastim (Neulasta), Followed by Maintenance Rituximab in Elderly/Poor Performance Status Patients with Large B-Cell Non-Hodgkin’s Lymphoma

PIX 301

Pixantrone (BBR 2778) versus other chemotherapeutic agents for third-line single agent treatment of patients with relapsed aggressive NHL: A randomized, controlled, phase III comparative trial

SWOG S0106

A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) Induction Therapy versus Standard Induction with Daunomycin and Cytosine Arabinoside followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients under Age 56 with Previously Untreated deNovo Acute Myeloid Leukemia (AML)

SWOG S0016

A Phase III Trial of CHOP + Rituximab vs. CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphomas

SWOG S0313

Evaluation of CHOP Plus Involved Field Radiotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE, and Non-Bulky Stages II and IIE CD20 Positive, High-Risk Localized, Aggressive Histologies of Non-Hodgkin’s Lymphoma, Phase II

DACO-016

Randomized Phase 3 Trial of Decitabine versus Patient’s Choice with Physician’s Advice of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia

MELANOMA

Luitpold

Phase III study of Taxoprexin injection versus Dacarbazine in patients with metastatic malignant melanoma

LUNG

RTOG 0412/
SWOG S0332

Phase III Randomized Trial of Preoperative Chemotherapy versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients with Stage IIIA (N2) Non-Small Cell Lung Cancer

OSI3364g Tarceva

A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with TarcevaÔ (Erlotinib) Compared with Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) after Failure of Standard First-Line Chemotherapy

Perifosine 201

A Phase I/II Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer

Bayer 11961 (Sorafenib)

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel plus or minus Sorafenib (BAY 43-9006) in Chemonäive Patients with Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

LUN 90

A Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive Stage Small Cell Lung Cancer

LUN 120

Phase II Study of Higher Dose Weekly Topotecan in the 2^nd Line Treatment of Patients with Relapsed Extensive Stage Small Cell Lung Cancer

PANCREATIC

We have no pancreatic studies at this time.

HEAD AND NECK

We have no head and neck studies at this time.

MISCELLANEOUS

CRASH

Chemotherapy Risk Assessment Score for High Age Patients; Design and Validation

Moffitt

UNK PRI 12

A Randomized, Phase III Comparison of Gemcitabine/ Irinotecan Followed by ZD1839 (Iressaâ) versus Paclitaxel/Carboplatin/Etoposide Followed by ZD1839 (Iressaâ) in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site

Perifosine 207

A Phase IIA Trial of Two Schedules of Perifosine in Patients for Whom No Standard Therapy Exists

GI Outcomes
(MCC 14495)

Total Cancer Care Quality Improvement Protocol for Colorectal Cancer

TCC—Total Cancer Care (MCC 14690)

Total Cancer Care: A Partnership with High Risk and/or Diagnosed Cancer Patients for Life

PBI

Partial Breast Irradiation Registry